TAG:
ameripath
Non-Pathologists Altering U.S. Laboratory Industry
By Robert Michel | From the Volume IX No. 13 – September 16, 2002 Issue
CEO SUMMARY: It’s an interesting contradiction. On one hand, most pathologists enthusiastically recognize the value that diagnostic testing services provide to the healthcare community. On the other hand, too often it is non-laboratorians who provide the investment capital and entrepren…
Two New Public Labs Launch Operations in FL
By Robert Michel | From the Volume IX No. 10 – July 15, 2002 Issue
CEO SUMMARY: In 49 states, independent commercial laboratory companies are disappearing. But that’s not the case in Florida. In recent months, two new public laboratory companies completed organizational steps and now offer diagnostic testing services. Both companies are starting small,…
Aetna, AmeriPath, DIANON, IMPATH, JCAHO
By Robert Michel | From the Volume IX No. 10 – July 15, 2002 Issue
AETNA RECOMMENDS PAYERS SUPPORT GENETIC SCREENING TESTS ALL LABORATORIANS SHOULD send a special note of thanks to Aetna Chairman and CEO John W. Rowe, M.D. for his recommendation that the health industry support the concept of genetic testing. He made these recommendations as part of speech…
“July 15, 2002 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume IX No. 10 – July 15, 2002 Issue
In many states, pathologists were hit by substantial increases in the cost of malpractice. In some states, like Pennsylvania, the market for medical malpractice insurance has deteriorated substantially. In the case of AmeriPath, Inc., the nation’s largest operator of hospital-based…
IMPATH Buys Tamtron In Surprise Decision
By Robert Michel | From the Volume IX No. 2 – January 28, 2002 Issue
CEO SUMMARY: In an unexpected announcement, IMPATH, Inc. announced it would purchase Tamtron Corp., the largest remaining independent vendor of anatomic pathology systems. It was just months earlier that Cerner Corporation acquired Dynamic Healthcare Technologies, Inc. and its CoPath™ p…
Path Trends For 2002 Show Future Direction
By Robert Michel | From the Volume IX No. 1 – January 7, 2002 Issue
CEO SUMMARY: Even as pressures to squeeze costs and consolidate within the pathology profession ease, a different set of market trends is exerting influence. Collectively, these trends portend the end of the small pathology group’s dominance of its local healthcare marketplace. It will …
“January 7, 2002 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume IX No. 1 – January 7, 2002 Issue
Here’s an early conjunction of: 1) consumer demand for sophisticated healthcare services; 2) healthcare ecommerce, and 3) telemedicine. In Cleveland and Boston, major health systems have introduced a Web-based “second opinions” service. In the case of the Cleveland Clinic Foundation…
2001’s Ten Big Stories Presage Future Direction
By Robert Michel | From the Volume VIII No. 17 – December 17, 2001 Issue
CEO SUMMARY: During 2001, few labs found themselves under intense pressure to change or react to dramatic events in the healthcare marketplace. Like 2000, this past year was marked by evolutionary progress, not revolutionary change. However, continuing signs indicate that consumers will p…
DIANON Systems, United Health, Aetna, Quest Diagnostics, Orchid, AmeriPath
By Robert Michel | From the Volume VIII No. 17 – December 17, 2001 Issue
DIANON SYSTEMS INKS NATIONAL AGREEMENT WITH UNITEDHEALTHCARE A NEW NATIONAL AGREEMENT between DIANON Systems, Inc. and UnitedHealthcare was announced last week. The agreement allows DIANON Systems to provide pathology and genetic testing services to all the…
Quest Buys New Jersey Lab, Lab Investors Cash In Stock
By Robert Michel | From the Volume VIII No. #15 – November 5, 2001 Issue
THERE’S LOTS OF BUYING and selling taking place among the public laboratory companies. On one side of the spectrum, Quest Diagnostics Incorporated announced the acquisition of Clinical Diagnostic Services, Inc., a private laboratory company based in Englewood, New Jersey. Clinic…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized